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Activation-induced cytidine deaminase (AID) is indispensable for somatic
hypermutation (SHM) and class switch recombination (CSR) in B cells. SHM
alters the affinity of an antibody for its corresponding antigen by introducing point
mutations within the variable region of the immunoglobulin (Ig) gene heavy chain
locus. CSR replaces the Igµ constant region with one of the downstream
constant region, thereby changing the physical properties of the antibody.
To study the molecular mechanism of AID in these two antibody
diversification events, I cloned, expressed and purified the recombinant AID
protein from E. coli and showed that it can deaminate cytidines within single-
stranded DNA molecules in vitro. In addition, I showed that AID does not have a
preference for mutational hotspot sequences within a short DNA oligo in vitro. By
studying truncated recombinant AID protein and AID point mutants I confirmed
that AID activity is due to its typical cytidine deaminase active site. Hence, the
role of AID in SHM and CSR is beneficial to an organism as it gives rise to
antibodies of high affinity and avidity crucial in clearance of the antigen by
humoral immune response.
Aberrant AID activity, however, can lead to c-myc/IgH chromosomal
translocations and ultimately to B cell lymphomas and plasmocytomas in mice.
Such translocations can also be detected in B cells stimulated to switch in vitro.  I
showed that switching B cells also upregulate Rae-1, a ligand for the NKG2D
activating receptor found on natural killer (NK) cells, which renders them
sensitive to NK attack. Furthermore, I demonstrated that IgH/c-myc
translocations can be detected in vivo in germinal center (GC) B cells of
immunized mice, and that these cells also express Rae-1. However, these calls
are found in same frequencies in NK+ and NK- mice, implying that NK cells may
be actively excluded from the GC. In addition, my data suggest a role for NK cells
in clearance of B cells bearing IgH/c-myc translocations outside the protective
environment of the germinal center.
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“ONO CEMO BITI U STA VERUJEMO,
ONOLIKO BITI KOLIKO VERUJEMO”
TIN UJEVIC
MOJOJ PORODICI I TETKI BRANKI S LJUBAVLJU
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1CHAPTER 1. INTRODUCTION
1.1 Immune System
The immune system of mammals relies on a combination of innate and
adaptive mechanisms to defend the host against a wide range of pathogens.  In
traditional classifications, innate immunity utilizes germline-encoded pathogen
recognition receptors to identify and respond to general non-self threats, while
adaptive immunity employs combinatorial and mutational strategies to generate
an exceedingly diverse set of antigen receptor specificities. But while the immune
system can be activated to respond to foreign invaders (also termed “non-self”), it
must also remain inert on encounter with self antigens (1, 2). An important
exception to this rule is recognition of some tumor cells as non-self, or perhaps
modified-self, so that the immune system can protect against cancer (3).
All cells of the immune system originate in the bone marrow from a
haematopoietic stem cell, which ultimately gives rise to very diverse progeny
which can be divided into two functional categories (4, 5). One group of cells, the
cells of the innate immune system, is able to recognize the common features of
pathogens to respond immediately (6). In contrast, the cells of the adaptive
immune system are able to mount a specific response only days after
encountering the antigen. During the time required for adaptive immunity to
develop, the innate response plays a crucial role in controlling an infection.
21.2 Innate Immunity
The innate immune system provides a fast and general response to
infection. Found in almost all multicellular organisms, this system was first
described a century ago and has only recently become a focus of research (7). It
recognizes highly conserved pathogen-associated molecular patterns (PAMPs)
by germ-line encoded Toll receptors (6). These receptors were first described in
Drosophila, and mammalian homologues were soon identified (8). Together, they
constitute a family of ten Toll-like receptor (TLR) proteins, each recognizing a
different microbial pattern (9). Phagocytic cells, such as macrophages and
neutrophils play an important role in innate immunity. They carry almost all TLR
receptors on their surface, which gives them the ability to recognize common
surface molecules on microorganisms, further allowing them to engulf and digest
them. Upon encountering bacteria, macrophages are also able to secrete
cytokines and chemokines, thus initiating inflammation of the infected tissue.
TLRs are also expressed on mast cells, which are also capable of phagocytosing
microorganisms as well as initiating a potent inflammatory response. In addition
to phagocytic cells, other granulocytes, eosinophils and basophils, play a crucial
role in parasitic infections and allergy responses respectively.
Another important cell type that mediates innate immunity is the NK cell. It
is of lymphoid origin, but unlike B and T cells, it lacks an antigen receptor. NK
cells provide the first line of defense against viruses and tumors; they will be
discussed in more detail later in the introduction.
31.3 Adaptive Immunity
In addition to the innate immune system, jawed vertebrates have
developed an anticipatory, or adaptive, immune system. Adaptive immunity rests
on the ability of the main effector cells, B and T lymphocytes, to diversify their
surface receptors and generate more than 1011 different antigen recognition
receptors.  Unlike the cells of the innate immune system, which recognize
general features of pathogens, B and T cells recognize specific antigenic
features of pathogens in the context of major histocompatibility (MHC) molecules,
after processing by antigen presenting cells.
Within the effector cell compartment there is a distinct delineation of
functions, with T cells are responsible for cell-mediated immunity and with B cells
providing humoral immunity. Generally, with the exception of superantigens, T
cells are unable to recognize a pathogen unless it is on the surface of antigen-
presenting cells such as dendritic cells (10). Therefore for T cells to effectively
recognize pathogens, these have to be encountered and ingested by dendritic
cells, which during that process mature into professional antigen-presenting cells
and in addition to presenting antigen acquire the ability to secrete specific sets of
cytokines (11, 12).  Once they encounter their cognate antigen, T cells become
activated: they undergo clonal expansion and differentiate either into cytotoxic T
cells or helper T cells. While cytotoxic T cells kill infected cells, helper T cells can
further activate cells such as macrophages and B cells, or help them maintain
their activated status, again through the secretion of particular sets of cytokines.
4On the other hand, B cells, upon encountering soluble antigen, further
diversify their receptor genes by somatic hypermutation to create antibodies of
higher affinity for the particular antigen. They also change the physical properties
of the antibody by switching the isotype (class switch recombination). Successful
cells are clonally selected to differentiate into plasma cells that secrete large
amounts of antibodies to combat infection. B cells that were not able to
successfully differentiate their receptor are negatively selected and deleted from
the repertoire.
1.3.1 B cells
B cells originate from a common lymphoid progenitor in the bone marrow
(4). The stages of B cell development are defined by a stepwise series of gene
rearrangements and expression of immunoglobulin (Ig) and other characteristic
proteins on the surface (Figure 1) (13-17). Early pro-B cell begins to rearrange its
heavy chain Ig gene by VDJ rearrangement. After DH to JH joining, pre-B cell
moves to the late pro-B stage undergoing VH to previously rearranged DJH
joining. Successful VDJH rearrangement leads to the expression of m heavy
chain on the surface together with a surrogate light chain, forming the pre-B-cell
receptor. This defines the next stage of development, the large pre-B cell.
Signaling by the pre-B-cell receptor is contingent upon a productive
rearrangement of the heavy chain, and the large pre-B cell divides, giving rise to
a small pre-B cell in which light chain rearranges and is expressed on the surface
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6replacing the surrogate chain to form a true B cell receptor; this defines the IgM+
immature B cell. Before immature B cell emerges from the bone marrow, it
undergoes negative selection for self-tolerance, i.e. auto-reactive cells are
eliminated (18). B cells that leave the bone marrow and survive in the periphery
further differentiate into mature B cells, expressing both IgM and IgD. These
cells, also called naïve B cells, travel through peripheral lymphoid tissues, where
they become activated if they encounter their cognate antigen.
1.3.2 Antibodies
The main function of B cells in defense of the organism is their ability to
evolve, produce and secrete large amounts of antibodies specific for a particular
antigen. Antibodies, also referred to as immunoglobulins, are a secreted form of
the B cell receptor, composed of a heavy (H) and a light (L) chain, each with two
distinct regions, called variable (V) and constant (C) (19, 20). The variable region
recognizes and binds the antigen, while the constant region governs the way
bound antigens are cleared from the body.
1.4 Diversification
1.4.1 VDJ Recombination
As mentioned before, lymphocytes are capable of recognizing a large
number of antigens, due to the series of genetic rearrangements that take place
within the Ig, or B cell receptor (BCR) gene. Antibody diversification begins
7before exposure to antigen during B cell development in the bone marrow with
the rearrangement of the variable (V), diversity (D) and joining (J) segments of
the immunoglobulin gene (Figure 2). VDJ recombination joins a single V, D, and
J segment into a single variable region through superbly well coordinated set of
reactions starting with cleaving DNA within specific, well-conserved
recombination signal sequences (RSS). This process is dependent on
recombination-activating genes 1 and 2 (RAG1 and RAG2) which together form
RAG endonuclease (21). Finally, DNA segments are re-assembled by common
repair mechanism.
Each coding segment is flanked by an RSS, and the RAG proteins
introduce double stranded DNA breaks between the coding sequence and RSS.
In fact, in test-tube experiments, RAGs are sufficient to introduce DNA breaks in
the synthetic DNA oligonucleotide with appropriate RSS (22). These RSS consist
of highly conserved heptamer and nonamer sequences, separated by either a
12-mer or a 23-mer. A 12/23 rule states that if one RSS contains as 12-mer, the
second RSS has to contain a 23-mer for efficient recognition and cleavage by
RAG.
After cleavage, the double-stranded DNA breaks have to be repaired.
Imperfect joining of the segments in the non-homologous end joining reaction
(NHEJ), with nucleotides added or subtracted, adds to junctional diversity.  The
whole process has the potential to create as many as 1011 unique variable
regions from the germline immunoglobulin genes.
8Figure 2. Antibody diversification events. V (red), D (purple) and J (blue)
segments are recombined in VDJ reaction to yield a single variable region.
Somatic hypermutation introduces point mutations (X) with the newly formed
variable region. Class switch recombination proceeds via double stranded
DNA breaks in the switch regions (Sµ – yellow, Sγ, Sε, and Sα – fuscia). Sµ
is joined with a downstream S region, while the intervening DNA is looped
out. Constant regions are shown in turquoise.
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91.4.2 Somatic Hypermutation and Class Switch Recombination
Mature B lymphocytes that have successfully rearranged their Ig genes by
VDJ recombination migrate through the periphery and become activated once
they encounter an antigen. In secondary lymphoid organs, activated B cells
proliferate and form organized compartments called germinal centers (GC) (23)
where further diversification of Ig genes takes place: somatic hypermutation and
class switch recombination.
1.4.2.1 Somatic Hypermutation
Somatic hypermutation (SHM) introduces point mutations and small
deletions within the immunoglobulin V region of both heavy and light chains (24,
25), thereby changing the affinity of the antibody for antigen (Figure 2). The rate
of somatic hypermutation is about million times higher than the background level
of spontaneous somatic mutation.
Transcription is required for somatic hypermutation (26). It has been
shown that mutations can be found within Cκ, a gene that normally does not
mutate, when Ig promoter is duplicated upstream of Cκ (27). In addition, mutation
rates are directly proportional to the transcription rates throughout the locus (28).
For example, when a mutant gfp gene, carrying a revertible stop codon, is cloned
under tetracycline-inducible promoter and transfected into B cells, the levels of
reversion mutations are directly correlated with the levels of transcription (28).
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Additionally, the mutation initiation site is determined by the distance from
the promoter (27, 29). SHM has been shown to peak about 200 base pairs after
the promoter, and frequency decreases exponentially with distance from
promoter (30). The Ig enhancers have been shown to be important and perhaps
necessary for SHM, as their presence facilitates mutation but their absence does
not completely abolish it (31-35). Mutations are clustered within the
complimentarity determining regions, which are shown to form the binding site in
the three-dimensional structure of the antibody (36). Although it is not sequence
specific, mutation shows preference for certain mutational “hotspot” motifs
(RGYW/WRCY, where R=A/G, Y=C/T, and W=A/T; or better yet DGYW/WRCH,
where D=A/G/T, and H=T/C/A), which are at least twice as likely to be mutated
than other sequences (37, 38). However, this sequence is not responsible for
targeting of mutation since not every RGYW motif is targeted (39).
It is important to note that Ig genes are not the only genes that can be
mutated, and I will further expand on this issue in the discussion (see Chapter 6).
1.4.2.2 Class Switch Recombination
The constant region of the Ig heavy chain locus consists of several C
genes, which are directly preceded by switch regions (S) (Figure 2). Class switch
recombination replaces the default Ig constant region, Igµ, with a downstream
constant region, Cγ, Cε, or Cα (Figure 2). This results in changing the antibody
protein isotype from IgM to IgG, IgE or IgA respectively, while retaining the
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antibody specificity for antigen while altering the physical properties of the
antibody. This recombination takes place between two switch regions, while the
intervening DNA is looped out and eventually removed (40, 41).
Switch regions are different in nucleotide sequence, but they are all highly
repetitive. In mice, Sµ region primarily contains pentameric units that are
repeated throughout (42), while repeats within Sγ contain 49 base pairs, repeats
in Sε contain 40 base pairs (43), and finally repeats in Sα repeats are the largest,
consisting of 80mers (44). This is not unique to mice, as switch regions of other
species, including humans, show similar sequence patterns (45). In addition to
being highly repetitive, switch regions also contain palindromic sequences, which
allow for formation of stem-loops when DNA is denatured. Switch regions are
necessary for CSR, as their deletion results in complete abolishment of the
reaction (46, 47). However, it appears that the features of switch regions (such
as repetitive and palindromic sequences) are more important than the sequences
themselves. For example, when Sα was replaced by Sε in the CH12F3-2 model
cell line that specifically switches to IgA, the efficiency of this reaction was
retained (48). Also, changing the orientation of Sα region did not unduly influence
switching efficiency.
Initially, breaks are made within switch regions directly preceding the
constant regions participating in recombination (49, 50). Although these can be
detected as blunt ends by ligation-mediated PCR (51), it is unclear whether they
are clean double stranded breaks as opposed to nicked cleavage breaks, or
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even staggered breaks made blunt by post-cleavage processing. Nevertheless,
double stranded DNAs breaks are CSR-specific.
These newly formed breaks have to be repaired in order to preserve
genomic stability. It is thought that the intervening DNA sequence is looped out,
and the breaks themselves are repaired by a non-classical NHEJ pathway (52-
54). Proteins required for NHEJ (DNA-PKcs, Ku-70 and Ku80) are also required
for CSR (53, 55, 56). However, 53BP1, a protein induced upon genotoxic stress
(specifically DSBs), is also required for CSR, as its deficiency is shown to
produce significantly lower levels of switch junctions (54, 57). There is no
sequence consensus at the newly formed joints, and no homology between the
parental sequences. The newly repaired DNA will give rise to the new transcript,
reading the desired constant region.
Transcription is necessary for CSR, and it appears to play a role in
selection and targeting of a particular S region, as different cytokines initiate
transcription of different S regions (58, 59). The levels of transcription directly
correlate with the levels of recombination (60), as it has been previously
mentioned for SHM.
1.4.3 Activation-Induced Cytidine Deaminase (AID)
Although seemingly very different, both SHM and CSR have been shown
to depend on a presence of a single enzyme: activation-induced cytidine
deaminase (AID) (61). AID was first discovered as CSR specific factor by
13
subtraction hybridization of cDNA libraries of switch-induced and uninduced
CH12F3-2 cells (62). Furthermore, overexpression of AID in the same cell line
enhanced levels of CSR, regardless of other stimulants, such as cytokines.
 Mice and humans lacking AID undergo neither somatic hypermutation nor
class switch recombination. AID-deficient mice do not mutate V regions of their Ig
genes, even upon immunization with a common immunogen such as NP-ova
(61). At the same time, IgG, IgE, and IgA titers are not present in blood of AID-
deficient animals, with or without prior immunization (with the exception of young
animals that carry maternal IgG). The only isotype that can be detected is IgM. In
addition, B splenocytes isolated from AID-deficient mice fail to switch their
isotypes when stimulated by LPS and IL-4 ex vivo. Furthermore, both mice and
humans deficient in AID show signs of Hyper IgM Syndrome: their spleens are
enlarged and blood IgM titers are high, but they do not produce any other
antibody isotype (63). Mutations are not found within V regions of Ig genes in B
cells from AID-deficient patients.
AID is a relatively small protein (198 amino acids, ~ 25 kDa), encoded by
a large gene (2500 bp) on human chromosome 12p13 (62, 64). A small part of
the gene encodes the active protein (594 bp), while most of the mRNA consists
of a long 3’ untranslated region. AID has been identified in all higher vertebrates,
starting from cartilaginous or bony fish, consistent with the observation that they
hypermutate (65-67).
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AID is almost exclusively expressed in germinal center B cells (62):
precisely the type of cells undergoing SHM and CSR in vivo. When
overexpressed, AID can mutate non-germinal center B cells, such as
hybridomas, suggesting that AID does not require any centroblast specific factors
for SHM (68). Furthermore, overexpression of AID in non-B cells, such as NIH-
3T3 fibroblasts, leads to mutations in artificial substrates (69). The levels of
mutation can be correlated to levels of transcription, and the distribution of
mutations is very similar to SHM in B cells, suggesting that AID is the only B cell
specific factor required for mutation. Most strikingly, overexpression of AID
mutated the RpoB gene in Escherichia coli (70). At the same time, AID
transgenic mice show increased accumulation of mutations in T cells (T cell
receptor gene and MYC oncogene), as well as increased incidence of T cell
lymphomas (71). Together, these data indicate that AID alone is sufficient to
cause mutation in highly transcribed genes, although under physiologic
circumstances it is restricted to the Ig locus in B cells.
Cytidine deaminases are characterized by a bipartite active site (72), and
AID is no exception. Centrally located, the first part of the active site (H56VE58L) is
involved in proton shuffling, followed by the zinc coordinating domain (C87YDC90):
both necessary for cytidine deamination (72).
AID is homologous to APOBEC-1, a catalytic subunit of the RNA-editing
complex of apolipoprotein-B mRNA (62). APOBEC-1 deaminates cytosine at
position 6666 of this mRNA, converting it to uracyl and thus giving rise to a new
15
mRNA, which is then translated into a shorter protein that forms chilomicrons (73,
74). APOBEC-1 is also found on human chromosome 12p13 (64), close to AID.
Because of their homology, as well as close genetic mapping, it was initially
proposed that AID acts on one or more mRNA molecules, thereby giving rise to
novel proteins that would function in SHM and CSR, but no RNA targets have
been identified (61, 75-78).
On the other hand, it has been shown that uracil DNA glycosylase (UDG)
is also involved in both somatic hypermutation and class switch recombination.
This enzyme is responsible for recognition and elimination of uracil when it is
found within DNA. When UDG is blocked by a specific inhibitor, the SHM
mutation spectrum is skewed and CSR is severely reduced, suggesting that AID
may be converting cytidines within DNA directly to uridine (79, 80). A large part of
my thesis work is devoted to understanding the biochemistry of AID, and my
work on this will be discussed in later chapters.
1.5 B Cell Lymphomas
Like any other cell type in human body, B cells can become malignant.
Lymphomas are cancers of the lymphatic system; B cell lymphomas are the most
common, representing about 85% of all lymphomas, with the remainder being T
cell lymphomas and NK cell lymphomas.
Chromosomal abnormalities were long postulated to be a cause of cell
transformation and malignancy, but it was only in 1960 that a marker
16
chromosome, the Philadelphia chromosome, was strongly associated with
chronic myelogenous leukemia (81). This abnormality was later characterized as
reciprocal chromosomal translocation between chromosomes 9 and 23 (82). B
cell lymphomas are often marked by chromosomal translocations (83-85),
involving the IgH locus and an oncogene locus, such as IgH/cyclinD1 (mantle cell
lymphoma (86)), IgH/bcl2 (follicular lymphoma (87)), and IgH/c-myc (Burkitt’s
lymphoma (88)). This genetic rearrangement results in deregulation of the
oncogene, leading to the transformation of the affected cell.
One of the best-characterized chromosomal translocations is IgH/c-myc
translocation, a hallmark of Burkitt’s lymphoma in humans, plasmocytomas in
mice and immunocytomas in rats (89-92). During this rearrangement, no genetic
material is lost or gained, so that the translocation is balanced and reciprocal. C-
myc, which is usually tightly regulated within a cell cycle, is thus brought to close
proximity and transcriptional regulation of a strong IgH promoter, resulting in its
deregulation and ultimately cellular transformation.
Analysis of IgH/c-myc junctions showed that most of these translocations
involve IgH switch regions, suggesting they arise from an anomalous resolution
of DNA breaks during the class switch reaction (88, 90, 93-98).  In fact, it has
been shown that AID is required for IgH/c-myc translocations in vivo (99). In this
study, IL-6 transgenic mice were treated with pristein oil to induce translocations,
and translocations were only detected in AID+/- mice, while they were absent in
AID-/- mice. Furthermore, divergent pathways seems to lead either to class switch
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recombination or IgH/c-myc translocation (100): although both events require AID
and proceed through double stranded DNA breaks, it is the resolution of breaks
that is different in the two processes in vitro. Hence, deficiency in tumor
suppressors such as ATM, p19 or p53 increases the observed frequency of AID-
induced translocations: the frequency of the translocations in p53-deficient B
cells stimulated to switch ex vivo is about 30 percent. However, p53-/- mice do not
succumb to B cell lymphomas in vivo, indicating that there must be additional
mechanisms of suppression.
1.6 NK Cells in Innate Tumor Immunity
Natural killer cells bridge the adaptive and innate immunity in fighting
pathogens and tumors. As one of the major effector cells of innate immunity, they
have an ability to recognize and eliminate some virus-infected cells and tumor
cells (101-103). NK cells were first recognized in 1970s by their spontaneous
cytotoxic activity towards tumors (104). Although of the same origin and B and T
cells, they are different in that they lack typical surface antigen receptors.
Instead, NK cells carry two types of germline encoded receptors, which
are either inhibitory or activating (107). The killer inhibitory receptor (KIR)
engages with MHC class I molecule on the target cell, and attenuates the
activation of NK cells through the activating receptors (108, 109). The discovery
of inhibitory receptors lead to the “missing-self” hypothesis: NK cells constantly
survey their surrounding for MHC-I expression, which inhibits their activation.
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Due to the constant engagement of inhibitory receptors with their ligands in a
healthy organism, and thus constant NK cells inactivation, it has been very
difficult to study activating receptors and their ligands, of which there are many.
An activating receptor of major interest, as it can be upregulated upon genotoxic
stress, is NKG2D, a type II dimer linked by disulfide bonds and containing lectin-
like domains(110, 111). The mouse homologue of NKG2D was readily identified
and only recently shown to bind H60 and Rae-1 as well as their human orthologs
MICA and MICB (112, 113).  The Rae-1 family of molecules is comprised of
α, β, γ and δ isoforms, and it is known to be induced in embryonic carcinoma cells
upon exposure to retinoic acid (114) and genotoxic stress (114, 115).
Transfection of Rae-1 into otherwise unsusceptible targets renders them
sensitive to NK killing (112). This interaction appears to be specific, as it can be
blocked by polyclonal serum made against soluble NKG2D. In particular, Rae-1
is expressed on some tumor cells, and the level of its expression correlates with
the ability of NK cells to eliminate these tumors (116).
During my thesis work I have hypothesized that DNA damage incurred by
B cells during CSR-dependent translocations leads to Rae-1 expression on their
surface and eventual clearance by NK cells. Data pertaining to this hypothesis
will be discussed in later chapters.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Mice
All mice were purchased from Jackson Labs, with the exception of AID-/-
mice, which were a kind gift from Dr. Tasuku Honjo and were obtained from Dr.
Michel Nussenzweig. The following strains were used in the study: C57BL/6J
(000664), Balb/cByJ (001026), B6.MRL-FasLpr/J (000482), B6.129S2-Trp53tm1Tyj/J
(002101).
2.2 Purification of strepAID and AID-his
Human AID constructs, wild type and catalytic site mutant
(E58Q/C87,90A) were cloned into the pET-3d vector (Novagen) and transformed
into Rosetta bacterial strain (Novagen). Transformed bacteria were grown in LB
(EM Biosciences) and induced at OD600=0.8 with 2 mM IPTG for 3 hours at 37°C.
Bacteria were lysed with B-PER (Pierce), and lysate was pre-cleared on Q-
Sepharose FF (Amersham Biosciences) and loaded onto phosphocellulose P11
resin (Whatman). StrepAID eluted from P11 at 0.4 M KCl. Purified strepAID was
loaded onto MonoQ (Amersham Biosciences) and eluted as tetramer at 0.5 M
KCl.
Human AID constructs AID wt, coreAID (amino acids 1-158) and CTD
(amino acids 158-198) were cloned into the pET-28b vector (Novagen) carrying a
hexahistidine tag on C-terminus and transformed into Rosetta bacterial strain
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(Novagen). Transformed bacteria were grown in LB (EM Biosciences) and
induced at OD600=0.8 with 1 mM IPTG over night at 16°C. Bacteria were lysed by
high pressure (French Press) and DNA was sheared by sonication. The lysates
were spun down at 14,000 rpm for 30 minutes at 4°C and supernatants were
loaded onto the Co2+ resin (Talon). Column was washed with 30 mM imidazole,
and AID-his proteins were eluted with 150 mM imidazole. Further purification was
achieved by size exclusion chromatography on Sdex200 column (Amersham
Biosciences).
For all protein analysis, I used 4-20% gradient tris-glycine gels by Biorad
(161-1123). Coomassie staining was performed Simply Blue Safe Stain by
Invitrogen (LC6060), according to manufacturer’s instructions.  Silver staining
was performed by Silver Stain (ICN, 800665), according to manufacturer’s
instructions.
2.3 Electromobility Shift Assay (EMSA) and UV Cross-Linking
Oligonucleotide substrate (100 ng) was labeled by T4 polynucleotide
kinase (NEB) using 0.1 mCi γ-P32-ATP (Amersham). Binding reactions (1 ng
substrate and 200 ng strepAID in total volume of 10 µL; 10 mM Hepes pH 7.6,
10% glycerol, 100 mM KCl, 10 mM MgCl2, 0.1 mM EDTA and 0.5 mM DTT) were
incubated for 40 minutes at room temperature.
For EMSA the entire reactions were loaded on 4-20% polyacrylamide gels
(Bio-Rad Laboratories) and electrophoresed in tris-glycine running buffer at 100
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V on a Bio-Rad Laboratories Mini-Protean apparatus until the bromophenol blue
dye front had reached the bottom of the gel.
For UV cross-linking reactions were placed on ice 1.5 cm away from the
light source and exposed for 10 minutes at 254 nm in a Stratagene UV
Stratalinker. Samples were then heated to 95°C for 5 minutes in 1% SDS before
loading the 4-20% polyacrylamide gels electrophoresed at 200V with 0.1% SDS
in the running buffer. Gels were dried, and images were stored on phosphor
screens and analyzed on STORM or Typhoon Phosohoimagers with ImageQuant
software.
Substrates:
ssRNA: aUCGgaauguaugagaauaagaagagauaaugaauaauagaa
ssDNA: aTCGgaatgtatgagaatagaagagataatgaataatagaa
dsDNA (hp):
aTCGgaatgtatgagaatagaagagataatgaataatagaattctattattcattatctcttctattctcatacattc
CGAt
2.4 Deamination Assay – Thin Layer Chromatography (TLC)
All deamination assays were done in a buffer containing 10 mM Hepes pH
7.6, 100 mM KCl, 5 mM EDTA at 30°C. The radiolabeled substrates (CTP, dCTP,
RNA and DNA) were incubated with protein (cdd, strepAID, Apobec-1 or BSA) for
1 hour. Reactions were extracted with phenol:chloroform (Sigma) and digested
with P1 nuclease (Roche). Resulting mononucleotides were loaded onto a TLC
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plate (PEI cellulose; Merck), and plates were developed in a solvent system
containing isopropanol:hydrocloric acid:water (7:2:1) for 12 hours. Plates were
exposed to phospho-storage screens (Amersham Biosciences), which were
scanned by Typhoon imager and analyzed using ImageQuant software
(Molecular Dynamics).
2.5 Deamination Assay – Single Nucleotide Primer Extension (SNuPE)
All deamination assays were done in a buffer containing 10 mM Hepes pH
7.6,100 mM KCl, 5 mM EDTA at 30°C. However, AID was able to deaminate
DNA in a range of conditions: pH 7.6-9.0, 50 – 100 mM KCl and 23-37°C.
Ten nanograms of gel-purified oligonucleotide substrates were incubated with
100-200 ng AID for 30 minutes. A tenth of reaction was used for primer extension
with a thermophilic Klenow fragment Bst Polymerase (NEB). Briefly, a 25 µL
reaction containing 1 ng template, 1 ng primer and Bst buffer was incubated at
70°C for 1 minute, before addition of 0.5 units Bst. The reaction temperature was
first lowered to the appropriate primer annealing temperature for 10 seconds and
then raised to 65°C for 1 minute to allow for extension. Reaction was terminated
by the addition of sample loading buffer, heated to 95°C and loaded on 14% urea
denaturing gel (Sequagel, National Diagnostics). Gels were dried and exposed to
phosphor storage screens (Amersham Biosciences), which were scanned on
Typhoon imager and analyzed using ImageQuant software (Molecular
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Dynamics). All RNA oligos were custom synthesized by Dharmacon, Inc.; DNA
oligos were made by FisherOligos.
Substrates:
ACCint: agtaaatgaaACCgaatgtatgagaatagaagagataatga
ACCend: aACCgaatgtatggagaatagaagagataatgaataatagaa
TCGint: agtaaatgaaTCGgaatgtatgagaatagaagagataatga
TCGend: aTCGgaatgtatgagaatagaagagataatgaataatagaa
Primers:
PrExACC: atctcttctattctcatacattcG (Tannealing = 58°C)
PrExTCG: atctcttctattctcatacattcC (Tannealing = 57°C)
2.6 Transcription-based Assay for AID Activity
100 µL in vitro transcription reactions containing: 20 mM TrisHCl pH 7.9,
20 mM KCl, 5 mM MgCl2, 2 nM ptac-KanL94P plasmid, 10 nM RNAP (Epicentre),
100 µM rNTPs and 20 nM AID were incubated at 37°C. Plasmid DNA was
purified by Qiagen MinElute to yield 10 microliters of DNA in water, which was
electroporated into UDG-deficient E.coli. Bacteria were plated on spectinomycin
or spectinomycin/kanamycin/IPTG containing plates. The ptacKanL94P plasmid
was obtained from Dr. Michel Nussenzweig.
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2.7 Class Switch Recombination In Vitro and Rae-1 Detection
Resting B cells are isolated from mouse spleens by negative selection
using αCD43 magnetic beads (Miltenyi Biotec) according to the manufacturer’s
instructions. They were plated at concentration of 500,000 cells/mL in a 24-well
plate (Fisher), and stimulated to switch with LPS (25 µg/mL) and Il-4 (5 ng/mL)
(both from Sigma). Isotype switching was measured by surface expression of
IgG1 and IgG3 by FACS (BD Biosciences). Biotinylated αIgG1 (553441) and αIgG3
(553401) antibodies were used as the primary staining, and SA-PerCP (340130)
was used as the secondary antibody (all from BD Biosciences Pharmingen).
Data were analyzed by FlowJo software (FlowJo). αRae-1 primary antibody
(MAB17582) or isotype control (MAB0006) were used for the primary staining for
Rae-1 expression, followed by αRat-PE (F0105) (all from R&D Systems, Inc.).
2.8 NK Cytotoxicity Assay
NK cytotoxicity CyToxiLux® Plus (OncoImmunin, Inc.) was used according to
manufacturer’s protocol. Briefly, stimulated B cells were taken at the appropriate
time point (48, 60 and 80 hours post stimulation) and labeled with FL-2
fluorescing dye. 200,000 labeled B cells (target cells, t) were incubated with NK
cells (effector cells, e), freshly purified from congenic mice spleens by NK cell
isolation kit (Miltenyi Biotec, 130-090-864), in increasing ratios (t:e = 1:5, 1:10
and 1:20) for 1.5 hours. Caspase substrate was added to the reactions for 30
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minutes. The level of B cell killing was measured as function of caspase
substrate cleavage, indicated by fluorescence in the FL-1 channel.
2.9 Immunization and Germinal Center B Cell Isolation
Sheep red blood cells (CS1342; Colorado Serum Company) were diluted
1:10 with HBSS (GIBCO) and used to immunize mice (200 µL/mouse). Ten days
post immunization, mice were sacrificed and spleens and lymph nodes were
harvested. Germinal center B cells were sorted on FACSAria or FACSVantage
cell sorters (BD Biosciences), after staining with GL7-FITC (553666) and Fas-PE
(554258) antibodies (both from BD Biosciences Pharmingen). DNA was
extracted by standard methods and translocations were detected as previously
published (99).
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CHAPTER 3. AID IS A SSDNA DEAMINASE IN VITRO
AID has been shown to be necessary for SHM and CSR, and it was
initially postulated to be a functional cytidine deaminase acting on RNA (61).
Further studies have indicated that AID may act on DNA directly, as ectopic
overexpression of this protein results in dramatically increased levels of mutation
in non-germinal center B cells (68), non-B cells (69), and even Echerichia coli
(70). However, this effect could be achieved through a number of different
mechanisms. First, AID could be deaminating cytidine, dCTP or CTP, thus
altering the composition of cellular nucleotide pools, and even subtle pool
alterations can lead to mutagenesis in bacteria (117). Second, AID could act on
RNA, and overexpression of AID could lead to promiscuous mRNA editing, as
reported for overexpressed Apobec-1 (118). Finally, AID could deaminate DNA
directly. In fact, parallel work has convincingly identified uracil DNA glycosylase
(UDG) as a factor in somatic hypermutation (79, 80): ung would remove the
uridine product if cytidine is deaminated within the DNA molecule itself.
3.1 Recombinant Human AID Is a Tetramer
I took a biochemical approach to confirm that AID is indeed an active
cytidine deaminase and to determine which was the preferred deamination
substrate for AID in vitro. A wild type and a catalytic site mutant (E58Q/C87,90A)
human AID were cloned, carrying a small strep-tag on N-terminus. Both proteins
were overexpressed in E.coli and subsequently purified based on their affinity to
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bind phosphocellulose (P11) – a DNA mimic resin, that was known to
successfully bind various deaminases (119). AID eluted from P11 resin with a
peak at 0.4 M KCl to relative purity as shown by silver stain (Figure 3a).
To verify the identity of purified proteins, strep-AID wt and mutant were
boiled in SDS loading buffer, ran on a denaturing gel and Western-blotted using
two different reagents – streptavidin and αAID antibodies. In both cases, strep-
AID wt and mutant proteins migrated with a predicted size of a tetramer (Figure
3a). The tetramer was extremely stable, and could only be broken up by harsh
denaturants, such as Urea, Guanidine HCl, and EDTA (Figure 3b). These
experiments suggest that strep-AID is a tetramer when purified on a DNA mimic
resin. Indeed, many other deaminases are multimers (dimers, trimers and
tetramers), and many of them are stable on denaturing gels, such as Apobec-1
and BSD (120-122).
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Figure 3. Purified recombinant AID behaves as a stable tetramer. a) Purified
recombinant AID runs with a predicted size of a tetramer on a denaturing gel, as
shown by αAID western blot (left panel). The protein was nearly homogeneous
as shown by silver stain (right panel). b) Western blot that shows that strepAID
tetramer can dissociate into trimer and monomer upon boiling in buffers
containing strong denaturants and EDTA (lanes 2-4), but not in standard sample
buffer (lane 1) or EDTA alone (lane 5). Lanes 2-4 show samples boiled in 50%
formamide and 50 mM EDTA (lane 2), 0.8 M Urea and 50 mM EDTA (lane 3), or
25 mM Tris (pH 8), 10 mM EDTA, 2% SLS (lane 4). Protein size markers are
shown on the right.
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3.2 AID Does Not Deaminate Free CTP or dCTP
Many known and well described cytidine deaminases are metabolic (123,
124), acting on free bases such as CTP and dCTP. To find if recombinant
strepAID can deaminate CTP (or dCTP), the protein was tested in thin layer
chromatography (TLC) assay (125). Briefly, protein was incubated with
radiolabeled substrate (CTP or dCTP) and reactions were resolved on TLC plate.
When strepAID was incubated with α-P32-CTP or α-P32-dCTP for one hour no
conversion to α-P32-UTP or α-P32-dUTP was detected (Figure 4a). In contrast,
cdd, a metabolic cytidine deaminase from Bacillus subtilis, deaminated either
substrate almost quantitatively (Figure 4a). The same was observed in a
spectrophotometric assay (126). As expected, strepAID did not convert
CTP/dCTP to UTP/dUTP even after one hour, whereas cdd deaminated about
75% of the substrate within minutes (Figure 4b). This further strengthens the
finding that free CTP or dCTP cannot serve as strepAID substrate in vitro.
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Figure 4. StrepAID does not deaminate CTP. a) StrepAID (lane 3) cannot
deaminate CTP in standard thin layer chromatography assay, as compared to
metabolic deaminase, cdd (lane 2). Apobec-1 (lane 4) didn’t deaminate CTP.
BSA (lane 1) was used as negative control. b) StrepAID (yellow) and mutant AID
(pink) did not deaminate CTP in spectrophotometric assay, while cdd (blue)
quickly converted CTP to UTP.
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3.3 AID Binds Single Stranded Oligonucleotides In Vitro
After eliminating free bases, I considered other possible substrates such
as oligomeric nucleotides. To determine if strepAID can bind RNA and DNA, a
standard electromobility shift assay (EMSA) was performed. Indeed, strepAID
bound single stranded RNA and DNA, but not double stranded DNA (Figure 5a).
Binding to ssDNA was robust, as it could withstand a 25-fold excess of poly-dIdC
or tRNA competitors (Figure 5b). StrepAID bound oligonucleotides in the same
manner, regardless of presence or absence of cytidine within the sequence (data
not shown). Additionally, whereas wt strepAID bound both ssRNA and ssDNA,
mutant strepAID only showed binding to RNA (Figure 5b). This is consistent with
findings that mutants of better studied cytidine deaminases, such as Apobec-1,
lose substrate binding as well as catalytic activity when the cysteine residues of
the active site are replaced by other residues (127).
When binding reactions were UV-irradiated, the resulting protein-DNA
complex migrated on SDS containing gels with the approximate size of a
strepAID tetramer (Figure 6). More specifically, strepAID only cross-linked to
ssDNA, but not to dsDNA, or DNA:RNA hybrids (Figure 6). Mutant strepAID did
not cross-link to ssDNA, but did cross-link to RNA (Figure 6). Taken together, the
EMSA and UV cross-linking data suggest that ssDNA is a preferred substrate for
strepAID. This residual binding of mutant AID to RNA may be nonspecific and
due to the highly basic charge of the protein.
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Figure 5. Recombinant strepAID preferentially binds ssDNA. a) EMSA: AID
can bind ssDNA and RNA, but does not bind dsDNA. b) EMSA: active site
mutant of AID (m) retains some ability to bind RNA compared to wt, but cannot
bind ssDNA. Binding to ssDNA is resistant to 25 fold excess of tRNA or polydIdC.
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Figure 6. Recombinant strepAID uv-crosslinks to ssDNA and RNA. AID (wt)
can be uv-crosslinked to RNA and ssDNA, and the cross-linked species run with
a predicted size of a tetramer (black arrow). Mutant AID (m) can be uv-
crosslinked to RNA, and the bacterial cytidine deaminase cdd can be weakly
crosslinked to ssDNA (grey arrow).
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3.4 AID Does Not Deaminate RNA
To determine if AID could deaminate RNA, the protein was tested in a
standard thin layer chromatography (TLC) assay (125). Briefly, strepAID and
control proteins (BSA, Apobec-1) were incubated for one hour with a synthetic
RNA molecule, containing a single α-P32-labeled cytidine. The reactions were
phenol-extracted, digested by P1 nuclease, and the resulting mononucleotides
were loaded onto the TLC plate. The plate was developed to resolve cytidine
from its deamination product, uridine, by their difference in polarity: the more
polar cytidines are bound more tightly to the plate and migrate more slowly than
less polar uridines. Two different RNA substrates were tested: one containing the
labeled cytidine close to the 5’ end of the molecule, and another with the labeled
cytidine embedded within the molecule.
In this assay, strepAID was not able to deaminate a single cytidine found
at 5’ end of an RNA oligomer, comparable to the BSA negative control (Figure 7).
In contrast, Apobec-1, an RNA-editing deaminase, converted this cytidine into
uridine with great efficiency (Figure 7). When a different RNA oligomer, carrying
an internally labeled cytidine, was tested, strepAID remained inactive, whereas
Apobec-1 retained its activity (Figure 7). Despite binding to RNA, strepAID was
not able to deaminate two different RNA substrates in the TLC assay. It is
possible that strepAID could deaminate some specific RNA, or that it could only
deaminate cytidines within certain sequence context. However, based on these
findings, RNA is not a good substrate for strepAID in vitro.
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Figure 7. AID does not deaminate RNA in vitro. StrepAID (lane 4) did not
convert CTP to UTP when embedded in a short RNA molecule (left panel).
Apobec-1 deaminates RNA with great efficiency (lane 3). BSA (lane 1) and cdd
(lane 2) did not deaminate RNA. The same is shown in the right panel, except
that cytidine was closer to the 5’ end of the RNA molecule.
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3.5 AID Deaminates ssDNA In Vitro
To finally ascertain that strepAID can not only bind but also deaminate
ssDNA, the protein was first tested in a standard TLC assay, as for RNA above.
In this case, a DNA substrate containing a single α-P32-labeled cytidine was
incubated with strepAID for one hour, and the reaction processed as previously
described. StrepAID converted cytidine to uridine embedded in a DNA oligomer
(Figure 8). Although the deamination levels were low, they were consistent when
the assay was repeated several times.
Since the level of deamination observed was very low, I sought to confirm
this finding in an independent assay. In a single nucleotide primer extension
assay (SNuPE), a primer that stops just short of potential deoxyuridine is
annealed to DNA and extended by a single radioactive nucleotide. Under
stringent annealing conditions, DNA polymerases such as Taq or Bst
(thermostable Klenow fragment) only extend the primer if the radioactive
nucleotide available precisely complements the template (128). The reaction is
then analyzed on a sequencing gel, and the products are visualized by
autoradiography (Figure 9a).
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Figure 8. AID deaminates ssDNA in vitro. StrepAID (lane 2) deaminates
ssDNA, whereas BSA (lane 1) and mutant AID (lane 3) do not.
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Figure 9. Recombinant strepAID deaminates ssDNA. a) Schematic of SNuPE
reaction used to detect dC to dU conversion. b) The SNuPE reaction is specific:
given the template with a uridine at a known position, Bst will only extend the
primer with the addition of the complementary base (A*) and not any other
nucleotide (C*, T*, G*). c) U containing oligo serves as calibration curve – the
increasing signal corresponds to more uridine. d) BSA and mutant AID do not
deaminate DNA. StrepAID deaminates ssDNA. All shown in duplicates.
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To show that this assay is highly specific, a DNA oligonucleotide that
contained a single deoxyuridine within the sequence was tested in a SNuPE
reaction. Both Taq and Bst polymerases could extend the appropriate primer
when α-P32-dATP was present, but not in the presence of any other
radiolabelled nucleotide (Figure 9b). Furthermore, the primer could be extended
with α-P32-dATP only when deoxyuridine-containing oligo was used as a
template, but not when the template contained one of the other nucleotides (data
not shown).
To determine the sensitivity of this assay, a series of template dilution
SNuPE reactions was performed. Briefly, the template containing deoxyuridine
was diluted by increasing concentrations of template in which the deoxyuridine
was replaced by deoxycytidine. The SNuPE assay consistently detected the
deoxyuridine-containing oligo when it comprised as little as 1% of the total
template pool (Figure 9c). Hence, this assay allows for specific and sensitive
detection of deoxyuridine within DNA.
To measure the ability of strepAID to deaminate ssDNA, the protein was
incubated with an artificial oligonucleotide containing a single deoxycytidine close
to the 5’ end, and C-to-U conversion was detected by SNuPE assay. StrepAID
consistently deaminated ssDNA whereas the mutant protein failed to do so
(Figure 9c). The levels of cytidine deamination ranged anywhere from 1% to
10%, as assessed in comparison to standards containing uridine (Figure 9c). On
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top, strepAID could not deaminate dsDNA, as it would be predicted by lack of
binding to double stranded oligomers (Figure 9c).
Although strepAID showed very low levels of deamination activity, this
reaction occurred very quickly (within 10 minutes), and over a range of
conditions. Namely, strepAID deaminated ssDNA at varying salt concentrations
(50-150 mM), range of pH conditions (7.6-9.0) and temperatures (25-37°C), and
it could tolerate moderate levels of EDTA (5-10 mM). Taken together, these data
strongly suggest that strepAID is an active cytidine deaminase, and it is able to
convert cytidine to uridine within single stranded DNA swiftly and under a range
of in vitro conditions.
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CHAPTER 4. AID DEAMINATES DNA IN CONTEXT OF TRANSCRIPTION
Single stranded DNA is not readily available in vivo, raising a question:
where and when can AID find its substrate in a germinal center B cell? Single
stranded DNA may become transiently available during transcription, in which
case it would be predicted that AID activity must be tightly coupled to the
transcriptional apparatus, as previously envisioned (129). The first experiments
to support this notion were done in E.coli that have been transfected with two
plasmids: one carrying the AID gene under an inducible promoter, and the other
plasmid containing a mutated kanamycin resistance gene KanL94P under a
different inducible promoter. It was shown that induction of AID expression
together with the induction of transcription of KanL94P gene can lead to
reversion of L94P mutation and kanamycin resistance (130).
4.1 In vitro Transcription Provides ssDNA Substrate for AID
To show that transcription does not require additional E. coli proteins to
target deamination by AID, the ptac-KanL94P plasmid was incubated with
recombinant AID, E.coli RNAP and NTPs in vitro. After deproteinization,
reactions were electroporated into ung- E. coli cells which were plated on both
counting plates (containing spectinomycin) and selection plates (containing
spectinomycin, kanamycin and IPTG). The mutation frequency was then
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calculated as kanRspecR colonies (selected)/specR (total transformed) (Figure
10a).
In vitro incubation of ptac-KanL94P with AID alone did not appreciably
increase the frequency of mutation of the kanR gene (Figure 10b). The frequency
was slightly increased with addition of RNAP to the reaction, but it only reached
the in vivo levels in the context of transcriptional elongation after the addition of
ribonucleoside triphosphates. This is an underestimate of the actual frequency of
the AID-mediated mutations, since to be selected, clones carrying the
deaminated plasmids must be able to grow in the presence of kanamycin.
The catalytic site mutant AIDC90H was also tested in this assay. As
expected, AIDC90H showed no activity in this assay (Figure 11).
4.2 AID Activity Maps to the Predicted Catalytic Site
To further characterize AID, I used secondary structure prediction
algorithms in conjunction with three-dimensional threading (3D-PSSM, (131)) to
delineate the core domain of AID (coreAID) comprised of amino acids 1-158, and
the C-terminal domain (CTD) comprised of amino acids 158-198. To confirm that
activity resided with the core domain the kanR gene was transcribed with E. coli
RNAP in the presence of AID wt, coreAID or the CTD (Figure 11). Predictably,
the CTD produced only background mutation in the presence of RNAP. However,
the coreAID was just as active as the full length protein (Figure 11). These data
suggest that the small his tag on the c-terminus of AID does not interfere with its
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Figure 10. In vitro transcription by E.coli RNAP allows AID access to
plasmid DNA. a) Schematic of transcription-based AID assay. b) In vitro
transcription/deamination assay. AID is only able to deaminate the plasmid when
ribonucleotides are added to the reaction.
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Figure 11. Delineation of AID domains. CoreAID mutates ssDNA, but CTD fails
to increase the level of mutation (left panel). Mouse AID (mAID) deaminates the
ptac-KanL94P plasmid when it is transcribed (grey) and not in the absence of
transcription (white). Active site mutant (C90H) as well as other mutants (L62A
and R24,112A) did not mutate the plasmid. Western blots shown in the bottom.
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function, and a single mutation within the catalytic site renders the protein
inactive.
This result clearly distinguishes two domains of AID. The core domain
contains the active site responsible for the deamination of cytidine, as described
for other cytidine deaminases. The c-terminal domain does not contribute to
catalytic activity of the protein, and its main function is probably in subcellular
localization, as shown by other groups (132, 133). As both the full length and the
core protein show the same levels of activity, it can be concluded that the C-
terminal domain does not contribute to substrate recognition and deamination in
this assay.
Overall, recombinant AID was shown to be active, and it is the first
enzyme within the family of cytidine deaminases shown to act on DNA,
specifically single stranded DNA. Although its main role is to introduce beneficial
mutations in the Ig variable region and induce switching of Ig isotypes, AID
activity has to be tightly controlled (134-136) in order to prevent DNA damage it
would induce if deaminating random cytidines within DNA.
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CHAPTER 5. NK CELLS ELIMINATE B CELLS HARBORING IGH/C-MYC
TRANSLOCATIONS
One of the possible outcomes of aberrant AID targeting and DNA repair is
ever so rare in vivo appearance of AID-dependent IgH/c-myc translocations. The
low frequency of the translocations can be ascribed to stringent regulation of
resolution and repair of DNA breaks, but also to clearance of abnormal cells that
escape from this pool.
I sought to determine if NK cells play role in targeting and clearance of B
cells carrying potentially malignant IgH/c-myc translocations.
5.1 Ex Vivo Splenic B Cells Upregulate Rae-1 Upon AID-Induced DNA Damage
It has been shown previously that several types of genotoxic stress
upregulate the NKG2D family of NK ligands on the surface of damaged cells
which are then cleared by NK cells (115). AID induces double stranded DNA
breaks within switch regions during CSR. I sought to determine whether this type
of AID-induced DNA damage, i.e. a single regulated double stranded break, can
upregulate activating ligands for NK cells, such as Rae-1.
Splenic B cells were purified from Balb/cByJ AID+/+ and AID-/- mice and
stimulated to undergo CSR with LPS/Il-4 in vitro. As expected, only AID wt and
not AID-deficient B cells switched the Ig surface isotypes to IgG1 and IgG3 as
shown by FACS analysis (Figure 12). In addition, switching AID wt B cells
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upregulated Rae-1 with peak expression at 60 hours post stimulation, while AID-
deficient B cells failed to do so (Figure 12 and 13). Not only is Rae-1 upregulated
only on B cells that are switching in culture, but also the peak of upregulation
coincides with the expression of AID in these cells. This shows that Rae-1
upregulation depends on the presence of AID in stimulated B cells in vitro. I
conclude that AID-induced DNA damage can upregulate Rae-1, while AID-/- B
cells that have been stimulated to undergo CSR fail to do so under the same
conditions.
5.2 Rae-1+ B Cells Can Be Targeted And Eliminated by NK Cells
Upregulation of Rae-1 due to genotoxic stress and its expression on
surface of the cells allows for recognition by NK cells. If Rae-1 on a target cell
engages with NKG2D on the effector NK cell, the target cell can be eliminated by
NK cell. To determine if Rae-1+ B cells can be targeted and eliminated by NK
cells, I used an NK cytotoxicity assay. Briefly, splenic B cells were stimulated to
switch with LPS and Il-4 in vitro. At a particular time point (48, 60 or 80 hrs post
stimulation), stimulated B cells were labeled with a red fluorescent die (FL-2) and
incubated with increasing ratios of NK cells (1:5, 1:10 and 1:20). The reaction
was then incubated with colorless caspase substrate that starts to fluoresce in
FL-1 channel upon cleavage by caspases from apoptotic B cells, and the toxicity
is assayed by shift in fluorescence in FL-1 channel (Figure 14).
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Figure 12. B cells undergo CSR in vitro upon LPS/Il4 stimulation and
upregulate Rae-1. CSR can be detected by FACS analysis: wt B cells switch
from IgM to IgG1 and IgG3 (top panel), whereas AID-/- B cells fail to do so (middle
panel). Bottom panel shows upregulation of Rae-1 at the same time points: wt
(black) and AID-/- (grey).
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Figure 13. Rae-1 is upregulated at 60 hrs. B cells were stimulated to undergo
CSR in vitro, and assayed for Rae-1 upregulation (blue) at various time points.
The maximum Rae-1 upregulation was achieved at 60 hours after stimulation in
wt B cells. AID-/- B cells failed to upregulate Rae-1. Isotype control is shown in
black.
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Figure 14. NK cytotoxicity assay. Stimulated B cells are labeled with FL-2
fluorescing dye and incubated with NK cells for 1.5 hours. Colorless caspase
substrate is added for 30 minutes. B cell apoptosis is indicated by FL-1
fluorescence once the caspase substrate has been cleaved.
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At 48 hours, while Rae-1 is still not upregulated in switching B cells, NK cell are
unable to induce apoptosis, even when present in large excess (Figure 15). At 60
hours, NK cells were able to target and eliminate AID wt Rae-1+ B cells (Figure
15). At high ratios of NK cells to B cells, the dying B cells comprised about 50
percent of the total B cell pool, suggesting highly effective NK targeting. This
coincided with peak upregulation of Rae-1 on stimulated B cells in culture. At a
later time point, at 80 hours, when Rae-1 is no longer detected on the surface of
switching B cells, NK cells were not able to induce apoptosis in B cells (Figure
15). Therefore, upregulation of Rae-1 on B cells stimulated with LPS/Il-4 in vitro
renders them susceptible for NK targeting and killing.
5.3 NK Cell Mediated B Cell Apoptosis Is Blocked by aRae-1 Antibody
To determine if NK cell mediated B cell apoptosis was directly due to Rae-
1 surface expression, switching B cells were pre-incubated with either αRae-1
antibody or an isotype control. Apoptosis was prevented only when B cells were
pre-incubated by specific αRae-1 antibody and isotype control did not have an
effect (Figure 16). Hence, switching B cells can be targeted and eliminated by NK
cells in vitro due to the expression of Rae-1 on their surface.
52
CASPASE SUBSTRATE
1:5 1:10 1:25
48 hrs
60 hrs
80 hrs
B 
CE
LL
S
B : NK
Rae-1
Figure 15. NK cells mediate B cell apoptosis in vitro. B cells were stimulated
to undergo CSR in vitro and coincubated with increasing number of NK cells at
various time points: 48 hours (top panel), 60 hours (middle panel) and 80 hours
(bottom panel). Maximum B cell apoptosis was recorded at 60 hours (54.9%).
Corresponding Rae-1 upregulation on B cells is shown on the right.
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Figure 16. αRae antibody blocks NK mediated B cell apoptosis at 60 hours.
B cells were stimulated to undergo CSR in vitro and incubated with isotype
control (middle panel) or αRae-1 antibodies (bottom panel) before being subject
to NK cytotoxicity assay. Only αRae-1 and not the isotype control blocked the NK
mediated B cell apoptosis (compare to top panel).
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5.4 IgH/c-myc Translocations Are Detected in p53-/- Mice In Vivo
Having established that AID-mediated lesions during CSR can lead to
NKG2D ligand expression on the surface of ex vivo switching B cells, I wanted to
know whether these cells may be cleared by NK cells in vivo.
IgH/c-myc translocations have been detected in switching B cells in vitro
though rarely, and their frequency is vastly increased in the absence of tumor
suppressors such as p53, ATM etc. (100). However, there are no reports of
detection of such translocations in switching or mutating (i.e. GC) B cells in vivo.
Consistent with the rarity of IgH/c-myc translocations in vitro CSR cultures,
I could not detect a single translocation in over 2x106 germinal center B cells
isolated from spleens 10 days post immunization with sheep red blood cells (data
not shown). This was not discouraging, as translocations are very rarely detected
even in wt B cells.
In contrast to wild type B cells, p53-deficient B cells have a much higher
frequency of translocations in vitro (100). However, no reports have been made
on the occurrence of IgH/c-myc translocations in p53-deficient animals in vivo.
Therefore, I first asked if I could detect such translocations after immunization in
vivo. In fact, IgH/c-myc translocations were detected in 1 in 100,000 germinal
center B cells from spleens (Figure 17), with a total of 1x106 cells assayed.
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Figure 17. IgH/c-myc translocations are detected in germinal center B cells
of p53-deficient mice. Left panel shows translocations on a ethidium bromide
stained gel, whereas the right panel shows the southern blot of the same gel (c-
myc probe). The results were identical when IgH probe was used. Top panel
shows derivate chromosome 12, and the bottom panel shows derivative
chromosome 15.
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These translocations differed from those reported in vitro: they were less
diverse in size, clustering at around 1 kb, with very few outliers. This is consistent
with an earlier report that while in unimmunized mice translocations ranged in
size from 1.9 to 7.5 kb, in immunized mice that size range was compressed to
2.1 to 4.7 kb (137). The translocations I observed varied in sequence (Figure 18),
suggesting that particular translocation hotspots are positively selected in vivo.
Having detected IgH/c-myc translocations in germinal center B cells in
vivo, I wondered whether p53-deficient cells carrying these translocations also
express Rae-1 on their surface and if so, could they be accessed and targeted by
NK cells? To test whether Rae-1 was expressed in GC B cells in vivo, I
immunized mice with sheep red blood cells (sRBCs), a potent immunogen. At
several time points after immunization the mice were sacrificed and their
splenocytes collected and stained with antibodies against the germinal center B
cell marker GL7 and against Rae-1. I found that GC B cells did in fact express
Rae-1 on their surface in an AID-dependent manner (Figure 19a). When purified,
the same cells were also targeted by NK cells in cytotoxicity assay ex vivo
(Figure 19b).  Hence, germinal center B cells upregulate Rae-1 on their surface
and can be targeted and eliminated by NK cells ex vivo, suggesting a role of NK
cells in suppression of translocation frequency in vivo.
If NK cells can target and eliminate germinal center B cells in vivo, then
depletion of NK cells from p53-/- animals might increase the frequency of cells
with translocations.
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AATTATCTAGACTTATTTCG
TTTCAGTTAAGTGTATTAGT
AAACTGAGGTGATTACTCTG
GTAAGGAGGGACCCAGGCTA
AGTTTAAAATATTTTTAAAT
AATTATCTAGACTTATTTCG
CCAGTCTCTGAGAGGGCATT
GGGATTACCTTTTGCGTTTG
AAGGGAGGTGTCTCTTATTA
GAAAGGGGAGTGGTTCAGGA
GAGGGAATTTTTGTCTATTT
TGACTTGGGGGAAACCAGAG
Figure 18. Breakpoint sequences of representative IgH/c-myc chromosomal
translocations in p53-deficient mice.
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Figure 19. Germinal center B cells upregulate Rae-1 and are eliminated by
NK cells ex vivo. a) Upregulation of Rae-1 in germinal center B cells from wild
type mice (thin line) or p53-/- mice (dashed line) 8 days after immunization. Rae-1
is not upregulated in AID-/- mice (grey line). All compared to isotype control (thick
line). b) Germinal center B cells from p53-/- mice can be targeted and eliminated
by NK cells in standard cytotoxicity assay.
59
However, when I depleted p53-/- mice of NK cells I did not observe such an
increase (data not shown). Furthermore, the same NK depletion protocol applied
to wild type mice did not raise the frequency of translocations to detectable levels
(data not shown). My data strongly suggest that the germinal center is a
protected environment, which shields cells carrying translocations. Indeed, recent
two-photon imaging experiments of NK cell interactions in the lymph node
suggest that NK cells form a largely fixed network localized in the DC and T
areas of the lymph node but excluded from the B cell areas (138).
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CHAPTER 6. DISCUSSION
6.1 AID And the Adaptive Immune Response
A unique feature of the immune system is its ability to adaptively respond
to antigenic encounter by altering the antigen receptor specificities in T and B
cells. While VDJ recombination alone provides for more than a million T and B
cell receptors, B cells can undergo additional diversification to allow for perfect
recognition of soluble antigens. This additional diversification is achieved through
two reactions: the variable region is changed through somatic hypermutation and
the constant regions are exchanged in class switch recombination. Although they
both occur in response to antigen, SHM and CSR seemed mechanistically quite
distinct. Surprisingly, the recent discovery of AID has linked these two processes,
as mice and humans deficient in AID neither mutate their antibodies nor switch
isotype.
The discovery of AID opened up the field of antibody diversification and B
cell biology in general, leading to some quite exciting findings. First, AID was
shown to be a DNA-editing cytidine deaminase, and as such it was the first
enzyme in the family of cytidine deaminases to cause direct mutations in DNA.
Second, although the AID-induced DNA mutations are beneficial to the host and
only arise in response to antigen activation of B cells, it was shown that AID-
induced DNA damage can be detrimental to cells, leading to chromosomal
translocations and tumorigenesis.
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6.2 AID Is a DNA Editor
Prior to the discovery of AID in 1999 (62), all characterized cytidine
deaminases fell into two categories: metabolic (119, 120) or RNA-editing (127).
AID was shown to convert free cytidine to uridine in solution in vitro (62). It was
possible to imagine that this would skew the cell nucleotide pools, which would
then cause misincorporation of nucleotides within replicating V genes, ultimately
leading to high levels of mutation in SHM. This hypothesis never gained much
support, and I have shown that AID cannot deaminate free cytidine in vitro. The
activity on free cytidine that was originally described in this early paper was later
attributed to some contamination of a different deaminase in the protein
preparation (61).
Due to its homology to APOBEC-1, as well as their proximity on
chromosome 12p13, it was first postulated that AID would act on RNA (61),
possibly on two different mRNAs, which when edited would translate into two
distinct proteins, one of which would be necessary for SHM and the second one
for CSR. This offered an elegant explanation for the fact that one enzyme, AID,
was indispensable for two distinct molecular processes. Despite considerable
efforts, the specific RNA target has never been identified.
The early studies showed that AID can mutate non-germinal center B cells
(68), non-B cells (69) and even E. coli (70), together suggesting that AID is the
only B cell specific factor required for mutation. At about the same time, a parallel
line of work emerged, studying the role of UDG in immunoglobulin diversification
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events. Initially it was shown that inhibiting UDG with a specific inhibitor in DT40
chicken cell lines abrogated gene conversion (79), an antibody diversification
process also dependent on AID (139), but not discussed here in details. This
finding that AID and UDG might act in the same genetic pathway was further
strengthened when it was shown that somatic hypermutation is skewed and class
switch recombination is severely abolished in UDG-/- mice (80).
During my thesis work I showed that purified recombinant AID acts on
DNA directly (140), and more specifically, that in vitro, it binds and edits only
ssDNA. At the same time, three other groups have also shown that AID
deaminates ssDNA using different approaches (130, 141, 142). Therefore, it was
convincingly shown that AID is a DNA deaminase that acts on ssDNA in vitro.
This finding brought attention to one main question: where and when is
the ssDNA accessible in vivo? I hypothesized, as did others, that in vivo, single
stranded DNA is probably accessed during active transcription. Indeed, AID has
been shown to bind to the transcription elongation complex in vitro (143). After
this initial characterization of AID as the first DNA-editing cytidine deaminase,
others have been described. One example is Apobec-3G (144, 145), which
deaminates HIV-1 DNA as it is being reverse-transcribed in the cytoplasm of
infected cells. Newly synthesized viral DNA is digested and cleared, thus
preventing the integration of viral genome into the host genome and
establishment of permanent infection.
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The mutations induced by AID in variable or switch regions are beneficial
for the host. However, if the only requirements for acquiring these mutations are
presence of AID and active transcription, an important question clearly arises:
how is AID targeted to the appropriate locus at the appropriate time? And if this
restriction fails, how is AID-induced DNA damage repaired? There are as yet no
complete answers to these questions, but there are examples of AID
mistargeting, for instance, in mutating B cells, mutations are introduced in genes
other than Ig, such as bcl-2 (146, 147). In switching B cells, AID mistargeting, in
combination with anomalous repair, can lead to chromosomal translocations (99,
100).
6.3 Regulation of AID
Currently it is accepted that AID is DNA-editing enzyme, but it is still not
clear how its activity is regulated in B cells in order to minimize genomic damage.
AID appears to be a rate-limiting factor for mutation, as overexpression of the
protein increases the levels of SHM (148, 149). Therefore, the levels of AID
protein expression, its localization within the cell and other contributing factors
are important in regulating AID activity.
6.3.1 AID Expression
AID expression seems to be strictly confined to B cells, and especially
germinal center B cells (62). Obvious stimuli that induce AID expression are
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those that induce SHM in human lymphoma cell lines (IgM-CD19-CD21
crosslinking) and signals that induce CSR in splenic B cells ex vivo (a
combination of LPS, IL-4, CD40 and TGFβ). However, it is not clear which
pathways are responsible in delivering these signals to the nucleus and inducing
AID expression. Transcription factors of the E2A family, such as E2-2 and E47,
bind 2 E-boxes within the first intron of AID, thus playing a role in AID expression.
Other transcription factors, such as Pax5 and Id2 also have binding sites within
the AID promoter region and are important in regulation of levels of AID in the
cell (150). Overexpression of Pax5 induced AID expression in pro-B cells,
whereas overexpression of Id2 causes a decrease in AID expression, which
ultimately leads to diminished CSR.
AID is also upregulated in pro-B cells infected by a retrovirus (151), but
this line of work will not be discussed in detail here, first because how a retrovirus
induces AID expression is not understood and second, because the activity of
AID as a host response to viral infection is not restricted to the Ig locus and
therefore is qualitatively different than its activity during CSR and SHM.
6.3.2 AID Localization
Although AID is very small molecule that could easily diffuse through the
nuclear pore, it was first reported to be found mainly in the cytoplasm (149),
which would prevent it from accessing DNA and causing indiscriminate
mutations. Later studies have shown that AID carries a nuclear export signal
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within the last ten amino acids (132, 133), and it is thought to be actively
transported out of the nucleus. At the same time, it was reported that AID
contains a nuclear localization signal (NLS) located at its N-terminus (133).
However, this putative NLS does not appear to be autonomous, since it cannot
direct a large protein into the nucleus, while it also tolerates mutations of crucial
positively charged residues such as arginine and lysine (132, 152). Hence,
despite the presence of this putative NLS, how AID enters the nucleus remains
unclear.
Keeping AID out of the nucleus, and thus far from its target, is an
important way of restricting its action. Nevertheless, this still does not explain
how AID finds the appropriate locus (IgH), and how it distinguishes the variable
region from the constant region. In fact, it was shown that, when AID is
overexpressed in human lymphoma cell line, it is randomly mutagenic until cells
are specifically stimulated for hypermutation, focusing the mutations to IgH
variable locus (153). This was the first tangible demonstration of the existence of
reaction-specific AID partner proteins.
6.3.3 AID Co-factors
Many groups have unsuccessfully tried to identify AID partners that would
explain this preferential, locus-specific, targeting. The first protein to be co-
precipitated with AID was RNA Polymerase II (154), but the relevance of this
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interaction was largely dismissed, since AID activity correlates with transcription,
and the two enzymes are found in close proximity during SHM and CSR.
A couple of other proteins have also been described as potential AID
partners. Cascalho and colleagues have shown that AID can interact with DNA-
dependent protein kinase catalytic subunit (DNA-PKcs). However, this interaction
requires the presence of DNA as a cofactor, arguing against a direct interaction
of these two DNA binding proteins and thereby diminishing the relevance of
DNA-PKcs as a true partner (155). At the same time, Neuberger and colleagues
found that mdm2, an oncoprotein that shuttles between nucleus and cytoplasm,
can interact with AID in a yeast two-hybrid screen. However, they went on to
show that mdm2 is dispensable for antibody diversification, hence undermining
the relevance of this interaction as well (156).
A third putative AID partner protein is replication protein A (RPA) (157).
RPA is a trimeric complex, involved in replication, recombination and repair. The
32 kDa subunit of RPA was shown to interact with AID, and it was sufficient to
target AID to in vitro transcribed substrates harboring SHM motifs and enhance
the mutation rates of such targets. As a single stranded DNA binding protein,
RPA probably stabilizes the single stranded DNA as substrate for AID. Curiously,
RPA also interacts with UNG (158), and it is possible that it is important for
immediate recruitment of UNG and other repair proteins to the newly formed U:G
mismatches.
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As initially characterized, the AID-RPA interaction was dependent on
posttranslational modification of AID: only phosphorylated AID was able to bind
RPA, and this interaction was specific to B cells (157). Non-phosphorylated AID
can still deaminate ssDNA, but RPA-dependent deamination of actively
transcribed dsDNA substrate is markedly reduced (134). AID was shown to be
phosphorylated in B cells, at the protein kinase A (PKA) consensus site serine-38
(134-136). However, Nussenzweig and colleagues also found that AID is heavily
phosphorylated in 293T cells, presumably by PKA, a ubiquitous enzyme, thereby
calling into question the original claims of phospho-AID targeting to the V regions
of the Ig locus through interaction with RPA. They also found that phosphorylated
AID has much higher deamination activity (135) and that in contrast to 293T cells
only a small fraction of AID is phosphorylated in B cells, and that possibly this
form of AID accounts for the majority of SHM and CSR (135). Therefore, low
levels of phosphorylation may provide a way of keeping most of the AID in the
cell in an inactive, thus harmless form.
Given the uncertainty with the requirement for phosphorylation for the AID-
RPA interaction, the actual role of phosphorylation is now unclear. It is possible
that phosphorylation is important for AID stability and turnover in the cell,
perhaps playing a role in degradation. Phosphorylation might also be essential in
AID shuffling between nucleus and cytoplasm.
Finally, it is important to mention that PKA itself has been implicated in
control of B cell receptor signaling (159) and NFκB function (160). By controlling
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AID activity as well, PKA may play a major role in integrating the signals from
antigens and antibody diversification events.
6.4 AID Mistargeting Can Lead To Malignancies
When targeting mechanisms fail, mutations can be found not only in the
variable region of the immunoglobulin locus, but also in number of other genes
such as BCL-6 (161), CD95 (162) and many others. The mutation frequency of
the non-immunoglobulin genes is 50-100 fold lower than that of the Ig variable
region (162), but the pattern of mutation remains the same and the same
hotspots are preferentially targeted. When these aberrant mutations deregulate
targeted proto-oncogenes and tumor suppressor genes, they can cause
lymphomagenesis.
BCL-6 is a zinc-finger transcriptional repressor necessary for germinal
center formation and plays a role in B cell lymphoma pathogenesis (163, 164).
While it is one of the most common genes unintentionally mutated during SHM, it
is also very often involved in chromosomal translocations in follicular lymphoma
and diffuse large B cell lymphoma (165). Recent findings have shown that
deregulation of BCL-6 leads to repression of tumor suppressor gene p53, thus
suppressing a DNA damage-induced response in germinal center B cells (166).
However, physiologic levels of BCL-6 in B cell lines protect them from DNA
damage-induced apoptosis. Taken together, these data illustrate two important
points. First, BCL-6 plays an important role in germinal center B cells undergoing
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SHM and CSR by allowing them to tolerate the physiologic AID-induced DNA
breaks that accumulate during these reactions. Second, deregulated,
overexpressed BCL-6 contributes to cell transformation by silencing p53
repressor pathway.
Mistargeting of AID in context of class switch recombination can lead to
translocations, which once again lead to generation of lymphomas. One of the
best characterized case of AID-induced chromosomal abnormalities are IgH/c-
myc translocations, which lead to plasmocytomas in mice (167-172) and Burkitt’s
lymphoma in humans (173-181).
IgH/c-myc translocations require AID, as shown in AID+/+ Il-6 tg Balb/cByJ
mice treated with pristein in vivo (99). Thus, the translocations seemed to be
AID-induced. However, another study showed that, in a slightly different system,
translocations were AID-independent, and that presence of AID probably induced
secondary mutations that promoted survival of B cells already carrying AID-
independent translocation (182). However, IgH/c-myc translocations were
reproduced in an in vitro system in which B cells overexpressing AID were
induced to undergo CSR and no selective pressure is present (100).
Furthermore, the induction of translocations was dependent of AID catalytic
activity and UNG activity, suggesting that switch region breaks in CSR and IgH
breaks that lead to translocations can be generated by a common mechanism
involving these two enzymes. Moreover, double stranded DNA breaks within IgH
switch regions seem to be sensed by different proteins: p53 and p19 seem to
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play an important role in the pathway eventually leading to chromosomal
translocations and malignancy.
Therefore, chromosomal translocations involving IgH represent aberrant
switching reactions: they are AID-dependent, and they often involve IgH switch
regions (83, 86, 88). Indeed, the probability of such translocations occurring in
vivo, in an animal or human constantly exposed to antigenic stimulation so that B
cells are constantly undergoing CSR, is far greater than the observed frequency
of B cells with such translocations actually emerging from the germinal center
and becoming transformed and malignant. So, the question arises: why are
IgH/c-myc translocations infrequently observed in vivo? Or, from a different point
of view: what keeps the frequency of B cells with IgH/c-myc translocations at low
levels in vivo? Or, what eliminates these B cells in vivo?
6.5 Role of NK Cells in Maintenance of Healthy B Cell Population
 Most DNA damage is harmful and potentially malignant: therefore a cell
has many ways of sensing this damage, repairing it or signaling for help. Could it
be that switching B cells are sensing AID-induced DNA damage? I showed that
ex vivo switching B cells do in fact upregulate Rae-1, which is normally
upregulated upon genotoxic stress. Rae-1 is a ligand for NKG2D, an activating
receptor found on NK cells. Thus, by upregulating Rae-1 these B cells signal
their damaged genome to be recognized and killed by NK cells in vitro. This
drastic form of repair is exactly what I observed in vitro.
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Germinal center B cells are undergoing class switch recombination, and I
showed that they are also capable of upregulating Rae-1 eight days after
immunization. Furthermore, purified germinal center B cells can be targeted and
eliminated by NK cells ex vivo, as I showed in a standard cytotoxicity assay. This
result strongly suggested that NK cells could be important suppressors of
frequency of translocations in vivo.
6.6 Control of Frequency of Translocations In Vivo
In vitro data suggest that IgH/c-myc translocations occur in rather high
frequency in repair deficient background (100). For example, in vitro
translocations occur with about 30% frequency in p53-/- B cells (100), and I have
observed them with at least 10% frequency in p53-deficient mice in vivo.
However, p53-deficient mice rarely succumb to B cell lymphomas, and it is not
clear what factors are at work maintaining healthy B cell population in these
animals.
A clear link has been established between the genetic background of
animals and their predisposition to IgH/c-myc associated disease (137). In the
susceptible BALB/cAn strain plasmocytomas can be induced by intraperitoneal
injection of chemical carcinogens such as pristine in approximately 60% of
animals, whereas DBA/2 mice are completely resistant to tumor developments
(183). Nevertheless, no specific genes or functions have been defined as
important in controlling the frequency of translocations in vivo.
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I wondered if NK cells are important for maintenance of healthy B cell
population in vivo. I could detect IgH/c-myc translocations in p53-deficient mice in
vivo upon immunization with sheep red blood cells with about 10% frequency.
These translocations differed from those reported in vitro (100): they were less
diverse in size, clustering at around  1 kb, with some outliers bigger in size.
However, this was consistent with a report that in mice immunized with cholera
toxin, translocations were detected with size range of 2.1 to 4.7 kb, whereas they
ranged from 1.9 to 7.5 kb in unimmunized mice, still rare (137).
Somatic hypermutation and class switch recombination are physiological
landmarks of antigen-driven germinal center response, and the risk of genetic
lesions (and thus translocations) is greatly enhanced. In fact, T cells that do not
undergo such genetic rearrangements as CSR give rise to 10-20 times less
lymphoproliferative disease compared to B cells (184). Therefore, tight
checkpoints are in place which regulate positive and negative germinal center
selection, saving the useful B cell repertoire and eliminating the harmful cells.
The fact that translocations arising in immunized animals are less diverse in size
could be due to this stringent regulation and selection.
Are NK cells involved in suppression of these translocations in vivo? Mice
lacking NK cells do not show higher frequency of translocations. However, the
fact remains that NK cells are able to clear Rae-1+ B cells in vitro, and the
question arises whether NK cells can access switching B cells in vivo within
germinal centers. Together, my data suggest that, despite of fairly high frequency
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of translocations and the co-existent upregulation of Rae-1 in germinal center B
cells, NK cells are not able to access their targets in vivo. Indeed, a recent study
showed that NK cells are not found within the B cells areas in vivo (138).
However, one cannot exclude the possibility that NK cells still play an important
regulatory role in animals in which switching and mutation of Ig genes occur
outside of designated areas (i.e. germinal centers), such as MRLfas mice (185).
6.7 AID – Friend or Foe?
AID plays an important role in adaptive immune response, allowing a B
cell to evolve its antigen receptor, i.e. antibody, as required. Somatic
hypermutation and class switch recombination are efficient reactions, temporally
and spatially restricted to the immunoglobulin locus. The creation of a fit antibody
with high affinity for the antigen plays a crucial role in maintenance of a healthy
organism. However, when the control mechanisms fail, AID activity can lead to
chromosomal abnormalities and pathogenesis. The mechanism that regulates
AID targeting and restriction remains unknown, yet one can only imagine that
balance between perfect targeting and perfect repair will be central to the
explanation of the both the beneficial and the harmful effects of the activation-
induced cytidine deaminase.
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